CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors.
Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们提供了一种直接且有效的方法,以提高 CAR-T 细胞的低葡萄糖摄取水平,并改善其对实体瘤的抗肿瘤疗效。
葡萄糖剥夺抑制T细胞代谢和功能。实体瘤的肿瘤微环境中葡萄糖水平低,葡萄糖摄取不足限制T细胞的抗肿瘤反应。此外,葡萄糖限制可导致CAR-T(CAR-T)细胞疗法治疗实体瘤失败。然而,葡萄糖限制在CAR-T 细胞疗法中的影响仍未知。
检测了 CAR-T 细胞中的葡萄糖转运蛋白,并使其过表达。在体外和体内检测了葡萄糖限制对 CAR-T 细胞的影响。
葡萄糖限制显著降低了CAR-T 细胞的活化、效应功能和扩增。CAR-T 细胞高表达葡萄糖转运体Glut1,而Glut1对葡萄糖的亲和力较低。在葡萄糖限制条件下,Glut1的过表达未能改善CAR-T 细胞功能。相反,过表达Glut3可增强CAR-T 细胞的功能和抗肿瘤潜力,Glut3在Glut转运体家族中对葡萄糖的亲和力最高,并在CAR-T 细胞的一小部分中表达。过表达Glut3的CAR-T 细胞在多种异种移植瘤和同基因小鼠模型中显示出增强的杀肿瘤效力。此外,Glut3过表达激活了PI3K/Akt通路,并增加了OXPHOS和线粒体适应性。
Glucose deprivation inhibits T-cell metabolism and function. Glucose levels are low in the tumor microenvironment of solid tumors and insufficient glucose uptake limits the antitumor response of T cells. Furthermore, glucose restriction can contribute to the failure of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors. However, the impact of glucose restriction remains unknown in CAR-T cell therapy.
Glucose transporters were detected and overexpressed in CAR-T cells. The impacts of glucose restriction on CAR-T cells were checked in vitro and in vivo.
Glucose restriction significantly decreased CAR-T cell activation, effector function, and expansion. CAR-T cells expressed high levels of the glucose transporter Glut1, which has a low affinity for glucose. Overexpression of Glut1 failed to improve CAR-T cell function under glucose-restricted conditions. In contrast, the function and antitumor potential of CAR-T cells was enhanced by the overexpression of Glut3, which has the highest affinity for glucose among the Glut transporter family and is expressed in minor parts of CAR-T cells. Glut3-overexpressing CAR-T cells demonstrated increased tumoricidal efficacy in multiple xenografts and syngenetic mouse models. Furthermore, Glut3 overexpression activated the PI3K/Akt pathway and increased OXPHOS and mitochondrial fitness.
We provide a direct and effective approach to enhance low glucose uptake levels by CAR-T cells and improve their antitumor efficacy against solid tumors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。